Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment

  • Amer, Fatma
  • Yousif, Monkez M
  • Hammad, Noha M
  • Garcia Cehic, Damir
  • Nieto Aponte, Leonardo
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
Resistance-associated substitutions; RAS; Subtype 4a, Sustituciones asociadas a la resistencia; RAS; Subtipo 4a, Substitucions associades a la resistència; RAS; Subtipus 4a, Purpose: To study resistance-associated substitutions using next-generation sequencing in Egyptian hepatitis C virus-infected patients failing direct-acting antiviral treatment. Methods: The current study describes three cases of treatment failure in patients referred to Zagazig Viral Hepatitis Treatment Center (ZVHTC), Sharkia Governorate, Egypt. RAS were identified and characterized using deep sequencing. The first patient had breakthrough while receiving a daclatasvir (DCV)+sofosbuvir (SOF) regimen, patient 2 relapsed after treatment with DCV+SOF+ribavirin (RBV), and patient 3 relapsed after DCV+SOF therapy. A serum sample was collected from each patient at failure and sent to Vall d’Hebron Research Institute at Hospital Universitari Vall d’Hebron in Barcelona (Spain) for deep-sequencing study to identify and characterize the RAS present in the samples. Results: The following were identified: L28M, L30S and L28M+L30S in patient 1, L30R in patient 2, and R155C, D168E, L28M, L30H, L30S, L28M+L30H, and L28M+L30S in patient 3. Conclusion: To the best of our knowledge, this is the first report from Egypt of patients failing DAA-based therapy, describing the associated RAS. This information will be of help to understand the natural history of HCV in Egyptian patients and guide the proper choice of retreatment protocols., This study was supported by the Spanish Ministry of Health, Consumer Affairs, and Social Welfare, grant name: Plan Estrategico Nacional contra la Hepatitis C. This study was also funded by Instituto de Salud Carlos III, PI15/00856 and PI16/00337, cofinanced by CIBERehd (Consorcio Centro de Investigacion en Red de Enfermedades Hepaticas y Digestivas), which is funded by Instituto de Salud Carlos III and Centro para el Desarrollo Tecnologico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number, IDI-20151125
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients

  • Gonzalez Fernandez, Carolina
  • Casillas Gomez, Rosario
  • Carioti, Luca
  • Guerrero Murillo, Mercedes
  • Riveiro Barciela, Maria del Mar
  • Godoy Cruz, Cristina
  • Sopena Santisteve, Sara
  • Yll Pico, Marçal
  • Quer Sivila, Josep
  • Lopez Martinez, Rosa
  • Pacín Ruíz, Beatriz
  • García García, Selene
  • Esteban Mur, Rafael
  • Tabernero Caellas, David
  • Rodríguez Frias, Francisco
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Cortese, Maria Francesca
  • Buti Ferret, Maria
Haplotipos; Enfermedades infecciosas; Mutación, Haplotips; Enfermetats infeccioses; Mutació, Haplotypes; Infectious diseases; Mutation, Patients with HBeAg-negative chronic infection (CI) have not been extensively studied because of low viremia. The HBx protein, encoded by HBX, has a key role in viral replication. Here, we analyzed the viral quasispecies at the 5′ end of HBX in CI patients and compared it with that of patients in other clinical stages. Fifty-eight HBeAg-negative patients were included: 16 CI, 19 chronic hepatitis B, 16 hepatocellular carcinoma and 6 liver cirrhosis. Quasispecies complexity and conservation were determined in the region between nucleotides 1255 and 1611. Amino acid changes detected were tested in vitro. CI patients showed higher complexity in terms of mutation frequency and nucleotide diversity and higher quasispecies conservation (p < 0.05). A genotype D-specific pattern of mutations (A12S/P33S/P46S/T36D-G) was identified in CI (median frequency, 81.7%), which determined a reduction in HBV DNA release of up to 1.5 log in vitro. CI patients showed a more complex and conserved viral quasispecies than the other groups. The genotype-specific pattern of mutations could partially explain the low viremia observed in these patients., This study was supported by grants from the Institute of Health Carlos III (grant PI15/00856 and PI18/01436) and co-financed by the European Regional Development Fund (ERDF).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice, Comparison with Massive Sequencing

  • Nieto, Leonardo|||0000-0002-1336-5645
  • Quer, Josep|||0000-0003-0014-084X
  • Ruiz-Ripa, Alicia
  • Tabernero, David|||0000-0002-1146-4084
  • González, Carolina|||0000-0002-0169-5874
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Vila, Marta|||0000-0001-9303-5189
  • Asensio, Miriam
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Ruiz, Gerardo
  • Chen, Qian
  • Ordeig, Laura
  • Llorens, Meritxell
  • Saez, Montserrat
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
The unequivocal identification of hepatitis C virus (HCV) subtypes 1a/1b and genotypes 2 to 6 is required for optimizing the effectiveness of interferon-free, direct-acting antiviral therapies. We compared the performance of a new real-time HCV genotyping assay used on the Cobas 4800 system (C4800) with that of high-resolution HCV subtyping (HRCS). In total, 502 samples were used, including 184 samples from chronic HCV patients (from routine laboratory activity during April 2016), 5 stored samples with double HCV genotype infections for testing the limitations of the method, and 313 samples from a screening protocol implemented in our hospital (from May to August 2016) based on the new method to further determine its genotyping accuracy. A total of 282 samples, including 171 from April 2016 (the 13 remaining had too low of a viral load for HRCS), 5 selected with double infections, and 106 from screening, were analyzed by both methods, and 220 were analyzed only by the C4800. The C4800 correctly subtyped 125 of 126 1a/1b samples, and the 1 remaining sample was reported as genotype 1. The C4800 correctly genotyped 38 of 45 non-1a/1b samples (classified by HRCS), and it reported the remaining 7 samples as indeterminate. One hundred two of 106 non-1a/1b genotype samples that were identified using the C4800 for screening were confirmed by HRCS. In the 4 remaining samples, 3 were correctly reported as genotype 1 (without defining the subtype) and 1 was reported as indeterminate. None of the samples were misgenotyped. Four of 7 samples with double HCV infections were correctly genotyped by the C4800. Excluding the 5 selected double-infected samples, the C4800 showed 95.7% concordant results for genotyping HCVs 2 to 6 and 1a/1b subtyping, and 99.2% concordance for subtyping 1a/1b single infections in clinical samples. To improve laboratory workflow, we propose using the C4800 as a first-line test for HCV genotyping and 1a/1b classification, followed by transferring non-1a/1b samples to a center where HRCS is available, if further characterization is needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Analysis of hepatitis B virus preS1 variability and prevalence of the rs2296651 polymorphism in a Spanish population

  • Casillas, Rosario|||0000-0002-6758-6734
  • Tabernero, David|||0000-0002-1146-4084
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Belmonte, Irene|||0000-0002-8675-8343
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • González, Carolina|||0000-0002-0169-5874
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • López, Rosa Maria
  • Quer, Josep|||0000-0003-0014-084X
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
To determine the variability/conservation of the domain of hepatitis B virus (HBV) preS1 region that interacts with sodium-taurocholate cotransporting polypeptide (hereafter, NTCP-interacting domain) and the prevalence of the rs2296651 polymorphism (S267F, NTCP variant) in a Spanish population. Serum samples from 246 individuals were included and divided into 3 groups: patients with chronic HBV infection (CHB) (n = 41, 73% Caucasians), patients with resolved HBV infection (n = 100, 100% Caucasians) and an HBV-uninfected control group (n = 105, 100% Caucasians). Variability/conservation of the amino acid (aa) sequences of the NTCP-interacting domain, (aa 2-48 in viral genotype D) and a highly conserved preS1 domain associated with virion morphogenesis (aa 92-103 in viral genotype D) were analyzed by next-generation sequencing and compared in 18 CHB patients with viremia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy

  • González, Carolina|||0000-0002-0169-5874
  • Tabernero, David|||0000-0002-1146-4084
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Casillas, Rosario|||0000-0002-6758-6734
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Godoy, Cristina|||0000-0001-5037-1916
  • Sopena, Sara|||0000-0002-3309-5486
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Yll, Marçal|||0000-0002-7030-3360
  • Lopez Martinez, Rosa|||0000-0002-8450-6986
  • Quer, Josep|||0000-0003-0014-084X
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
To detect hyper-conserved regions in the hepatitis B virus (HBV) X gene (HBX) 5' region that could be candidates for gene therapy. The study included 27 chronic hepatitis B treatment-naive patients in various clinical stages (from chronic infection to cirrhosis and hepatocellular carcinoma, both HBeAg-negative and HBeAg-positive), and infected with HBV genotypes A-F and H. In a serum sample from each patient with viremia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

  • von Massow, Georg
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Macià, María Dolores
  • Escarda, Ana
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. During routine diagnostic, a sample from an Equatorial Guinea patient could not be classified into any of the existing subtypes. The whole genome was analyzed to confirm that the new isolate could be classified as a new HCV subtype. In addition, naturally occurring resistance-associated substitutions (RAS) were analyzed by NGS. Whole-genome analysis based on p-distances suggests that the sample belongs to a new HCV genotype 1 subtype. Several RAS in the NS3 (S122T, D168E and I170V) and NS5A protein (Q(1b)24K, R(1b)30Q and Y93L+Y93F) were found, which could limit the use of some inhibitors for treating this subtype. RAS studies of new subtypes are of great interest for tailoring treatment, as no data on treatment efficacy are reported. In our case, the patient has not yet been treated, and the RAS report will be used to design the most effective treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection

  • Godoy, Cristina|||0000-0001-5037-1916
  • Tabernero, David|||0000-0002-1146-4084
  • Sopena, Sara|||0000-0002-3309-5486
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • González, Carolina|||0000-0002-0169-5874
  • Casillas, Rosario|||0000-0002-6758-6734
  • Yll, Marçal|||0000-0002-7030-3360
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Lopez Martinez, Rosa|||0000-0002-8450-6986
  • Quer, Josep|||0000-0003-0014-084X
  • González-Aseguinolaza, Gloria|||0000-0002-1600-4562
  • Esteban, Rafael|||0000-0001-5280-392X
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
BACKGROUND Hepatitis delta virus (HDV) seems to strongly suppress hepatitis B virus (HBV) replication, although little is known about the mechanism of this interaction. Both these viruses show a dynamic distribution of mutants, resulting in viral quasispecies. Next-generation sequencing is a viable approach for analyzing the composition of these mutant spectra. As the regulatory hepatitis B X protein (HBx) is essential for HBV replication, determination of HBV X gene (HBX) quasispecies complexity in HBV/HDV infection compared to HBV mono-infection may provide information on the interactions between these two viruses. AIM To compare HBV quasispecies complexity in the HBX 5' region between chronic hepatitis delta (CHD) and chronic HBV mono-infected patients. METHODS Twenty-four untreated patients were included: 7/24 (29.2%) with HBeAg-negative chronic HBV infection (CI, previously termed inactive carriers), 8/24 (33.3%) with HBeAg-negative chronic hepatitis B (CHB) and 9/24 (37.5%) with CHD. A serum sample from each patient was first tested for HBV DNA levels. The HBX 5' region [nucleotides (nt) 1255-1611] was then PCR-amplified for subsequent next-generation sequencing (MiSeq, Illumina, United States). HBV quasispecies complexity in the region analyzed was evaluated using incidence-based indices (number of haplotypes and number of mutations), abundance-based indices (Hill numbers of order 1 and 2), and functional indices (mutation frequency and nucleotide diversity). We also evaluated the pattern of nucleotide changes to investigate which of them could be the cause of the quasispecies complexity. RESULTS CHB patients showed higher median HBV-DNA levels [5.4 logIU/mL, interquartile range (IQR) 3.5-7.9] than CHD (3.4 logIU/mL, IQR 3-7.6) (P = n.s.) or CI (3.2 logIU/mL, IQR 2.3-3.5) (P < 0.01) patients. The incidence and abundance indices indicated that HBV quasispecies complexity was significantly greater in CI than CHB. A similar trend was observed in CHD patients, although only Hill numbers of order 2 showed statistically significant differences (CHB 2.81, IQR 1.11-4.57 vs CHD 8.87, 6.56-11.18, P = 0.038). There were no significant differences in the functional indices, but CI and CHD patients also showed a trend towards greater complexity than CHB. No differences were found for any HBV quasispecies complexity indices between CHD and CI patients. G-to-A and C-to-T nucleotide changes, characteristic of APOBEC3G, were higher in CHD and CI than in CHB in genotype A haplotypes, but not in genotype D. The proportion of nt G-to-A vs A-to-G changes and C-to-T vs T-to-C changes in genotype A and D haplotypes in CHD patients showed no significant differences. In CHB and CI the results of these comparisons were dependent on HBV genotype. CONCLUSION The lower-replication CHD and CI groups show a trend to higher quasispecies complexity than the higher-replication CHB group. The mechanisms associated with this greater complexity require elucidation.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients

  • Gonzalez Fernandez, Carolina
  • Casillas Gomez, Rosario
  • Carioti, Luca
  • Guerrero Murillo, Mercedes
  • Riveiro Barciela, Maria del Mar
  • Godoy Cruz, Cristina
  • Sopena Santisteve, Sara
  • Yll Pico, Marçal
  • Quer Sivila, Josep
  • Lopez Martinez, Rosa
  • Pacín Ruíz, Beatriz
  • García García, Selene
  • Esteban Mur, Rafael
  • Tabernero, David
  • Rodríguez Frias, Francisco
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Cortese, Maria Francesca
  • Buti Ferret, Maria
Haplotipos; Enfermedades infecciosas; Mutación, Haplotips; Enfermetats infeccioses; Mutació, Haplotypes; Infectious diseases; Mutation, Patients with HBeAg-negative chronic infection (CI) have not been extensively studied because of low viremia. The HBx protein, encoded by HBX, has a key role in viral replication. Here, we analyzed the viral quasispecies at the 5′ end of HBX in CI patients and compared it with that of patients in other clinical stages. Fifty-eight HBeAg-negative patients were included: 16 CI, 19 chronic hepatitis B, 16 hepatocellular carcinoma and 6 liver cirrhosis. Quasispecies complexity and conservation were determined in the region between nucleotides 1255 and 1611. Amino acid changes detected were tested in vitro. CI patients showed higher complexity in terms of mutation frequency and nucleotide diversity and higher quasispecies conservation (p < 0.05). A genotype D-specific pattern of mutations (A12S/P33S/P46S/T36D-G) was identified in CI (median frequency, 81.7%), which determined a reduction in HBV DNA release of up to 1.5 log in vitro. CI patients showed a more complex and conserved viral quasispecies than the other groups. The genotype-specific pattern of mutations could partially explain the low viremia observed in these patients., This study was supported by grants from the Institute of Health Carlos III (grant PI15/00856 and PI18/01436) and co-financed by the European Regional Development Fund (ERDF).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment

  • Amer, Fatma
  • Yousif, Monkez M
  • Hammad, Noha M
  • Garcia Cehic, Damir
  • Nieto Aponte, Leonardo
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
Resistance-associated substitutions; RAS; Subtype 4a, Sustituciones asociadas a la resistencia; RAS; Subtipo 4a, Substitucions associades a la resistència; RAS; Subtipus 4a, Purpose: To study resistance-associated substitutions using next-generation sequencing in Egyptian hepatitis C virus-infected patients failing direct-acting antiviral treatment. Methods: The current study describes three cases of treatment failure in patients referred to Zagazig Viral Hepatitis Treatment Center (ZVHTC), Sharkia Governorate, Egypt. RAS were identified and characterized using deep sequencing. The first patient had breakthrough while receiving a daclatasvir (DCV)+sofosbuvir (SOF) regimen, patient 2 relapsed after treatment with DCV+SOF+ribavirin (RBV), and patient 3 relapsed after DCV+SOF therapy. A serum sample was collected from each patient at failure and sent to Vall d’Hebron Research Institute at Hospital Universitari Vall d’Hebron in Barcelona (Spain) for deep-sequencing study to identify and characterize the RAS present in the samples. Results: The following were identified: L28M, L30S and L28M+L30S in patient 1, L30R in patient 2, and R155C, D168E, L28M, L30H, L30S, L28M+L30H, and L28M+L30S in patient 3. Conclusion: To the best of our knowledge, this is the first report from Egypt of patients failing DAA-based therapy, describing the associated RAS. This information will be of help to understand the natural history of HCV in Egyptian patients and guide the proper choice of retreatment protocols., This study was supported by the Spanish Ministry of Health, Consumer Affairs, and Social Welfare, grant name: Plan Estrategico Nacional contra la Hepatitis C. This study was also funded by Instituto de Salud Carlos III, PI15/00856 and PI16/00337, cofinanced by CIBERehd (Consorcio Centro de Investigacion en Red de Enfermedades Hepaticas y Digestivas), which is funded by Instituto de Salud Carlos III and Centro para el Desarrollo Tecnologico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number, IDI-20151125